AOD 9604 is a modified fragment of human growth hormone (amino acids 176 to 191) marketed as a fat-loss peptide that stimulates lipolysis without the side effects of full growth hormone therapy. The clinical evidence behind it is thin: one Phase 2 trial from 2001 showed modest fat reduction, and the company that developed it abandoned further development after disappointing results. AOD 9604 has GRAS (Generally Recognized As Safe) status as a food ingredient. That is not FDA approval for weight loss, despite how frequently the distinction is blurred in marketing materials.
For autoimmune patients, weight management is not vanity. Obesity worsens disease activity in rheumatoid arthritis, psoriatic arthritis, and lupus. Excess adipose tissue pumps out TNF-alpha, IL-6, and leptin, inflammatory mediators that directly fuel autoimmune flares. The demand for weight management tools among autoimmune patients is real and legitimate. The question is whether AOD 9604, with its Grade C evidence, is the right tool when alternatives with dramatically stronger evidence exist.
Below: the mechanism, the trial data assessed honestly, the GRAS status explained, a head-to-head comparison with semaglutide, and where AOD 9604 fits (or does not fit) in an autoimmune weight management strategy.
What Is AOD 9604?
AOD stands for Anti-Obesity Drug. The peptide is a modified fragment of human growth hormone covering amino acids 176 through 191, with an added tyrosine at position 177 for stability. It was developed by Metabolic Pharmaceuticals in Melbourne, Australia during the 1990s.
The design logic was straightforward: isolate the fat-burning region of growth hormone from the growth-promoting and diabetogenic regions. Full growth hormone stimulates lipolysis (fat burning) but also raises IGF-1, promotes insulin resistance, and carries risks of joint pain, edema, and potential tumor growth. AOD 9604 was engineered to keep the lipolytic signal while discarding the rest.
AOD 9604 is banned by WADA (World Anti-Doping Agency), which tells you something about its perceived performance-enhancing potential. It is not FDA-approved as a drug for any indication.
Mechanism of Action
How AOD 9604 Promotes Fat Loss
AOD 9604 mimics the lipolytic domain of growth hormone. It stimulates the breakdown of stored triglycerides in adipose tissue (lipolysis) and inhibits the formation of new fat (lipogenesis). The mechanism involves activation of beta-3 adrenergic receptors on fat cells.
The key differentiator from full growth hormone: AOD 9604 does not stimulate IGF-1 production. This means it should not carry the insulin resistance, joint swelling, or tumor growth concerns associated with exogenous growth hormone therapy. The word "should" is important here. The evidence for this safety claim comes from limited studies, not long-term human data.
What AOD 9604 Does Not Do
AOD 9604 does not build muscle. It does not accelerate tissue repair. It does not suppress appetite. It does not reduce inflammation. It does not affect thyroid function. It is a narrowly targeted lipolytic fragment with a single proposed effect: fat metabolism.
This is worth stating plainly because the peptide marketing ecosystem routinely attributes benefits to AOD 9604 that have no supporting evidence. If a website lists immune modulation, joint repair, or cognitive enhancement as AOD 9604 benefits, that is fabrication, not science.
Clinical Evidence (Grade C)
The Heffernan Phase 2 Trial (2001)
The entirety of AOD 9604's clinical evidence rests on a single Phase 2 trial. Heffernan et al. enrolled approximately 300 obese adults across multiple dose groups and measured body composition changes over 12 weeks.
The 1 mg/day group showed modest fat reduction compared to placebo. "Modest" means approximately 2 to 3 kg of additional fat loss over 12 weeks. The primary endpoint did not achieve statistical significance across all dose groups.
Metabolic Pharmaceuticals subsequently attempted a Phase 2b/3 trial. The results were disappointing enough that the company abandoned AOD 9604 development entirely. When a pharmaceutical company walks away from a weight loss drug in a market worth tens of billions of dollars, the clinical signal was not compelling.
Why Grade C
We assign Grade C (preliminary evidence only) for the following reasons. There is only one published clinical trial. That trial showed modest results that did not consistently reach statistical significance. The developer abandoned further development. No peer-reviewed publication in a major medical journal followed. No head-to-head trial against an active comparator was conducted. No long-term efficacy or safety data exists.
Grade C means the compound has some human data suggesting biological activity, but the evidence is insufficient to recommend clinical use. Most peptide sites present AOD 9604 as if it were established medicine. It is not.
GRAS Status: What It Actually Means
AOD 9604 received GRAS (Generally Recognized As Safe) designation from the FDA in 2014 (GRN 000678). This designation allows AOD 9604 to be used as a food ingredient. It does not mean the FDA considers it effective for weight loss. It does not mean the FDA has approved it as a drug. It does not mean it has undergone the clinical trial process required for drug approval.
GRAS status evaluates safety for oral consumption as a food additive. It does not evaluate therapeutic efficacy. Many substances have GRAS status: caffeine, turmeric extract, various amino acids. None of them are "FDA-approved" treatments for disease by virtue of that status.
The peptide industry consistently conflates GRAS status with FDA approval. When you read that AOD 9604 is "FDA-recognized" or "FDA-accepted," the actual regulatory status is GRAS as a food ingredient. The distinction matters.
Why Weight Management Matters for Autoimmune Patients
The autoimmune relevance of weight management is not speculative. It is well-documented across multiple conditions.
Obesity Worsens Autoimmune Outcomes
Adipose tissue is not passive storage. It functions as an endocrine organ that produces TNF-alpha, IL-6, leptin, and resistin. These adipokines sustain chronic low-grade inflammation that worsens every autoimmune condition studied.
Specific data: obesity increases RA disease activity and reduces treatment response to biologics (Daien et al. 2021, Annals of the Rheumatic Diseases). BMI over 30 is associated with worse outcomes in psoriatic arthritis and higher biologic failure rates (Eder et al. 2015, Arthritis Care and Research). Obesity correlates with increased lupus flare frequency. Metabolic syndrome is 2 to 3 times more prevalent in RA and psoriatic arthritis compared to the general population.
Leptin, produced proportionally to fat mass, directly drives Th1 and Th17 polarization while suppressing regulatory T cells. This is a pro-autoimmune shift in immune balance caused by excess body fat.
The Autoimmune Catch-22
Many autoimmune patients face compounding barriers to weight management. Corticosteroids cause weight gain. Some DMARDs affect metabolism. Fatigue and joint pain limit exercise capacity. Thyroid dysfunction (particularly in Hashimoto's) slows metabolic rate. Sleep disruption from pain affects hunger hormones.
This creates genuine demand for weight management tools that do not require intense exercise or caloric restriction. The demand is valid. The question is which tools have evidence behind them.
AOD 9604 vs Semaglutide: Head-to-Head Comparison
This comparison is necessary because both compounds are marketed for weight management, and autoimmune patients deserve to see the evidence gap clearly.
Evidence quality. AOD 9604 has one modest Phase 2 trial (Grade C). Semaglutide has multiple large randomized controlled trials including the STEP program enrolling thousands of patients, FDA approval for both type 2 diabetes and obesity, and years of post-marketing safety data (Grade A).
Weight loss magnitude. AOD 9604 produced approximately 2 to 3 kg of additional fat loss over placebo in 12 weeks. Semaglutide (2.4 mg weekly) produced 14.9% body weight loss over 68 weeks in the STEP 1 trial (Wilding et al. 2021, New England Journal of Medicine). That is roughly 15 kg for a 100 kg person.
Anti-inflammatory effects. AOD 9604 has no demonstrated anti-inflammatory activity. Semaglutide and other GLP-1 receptor agonists reduce CRP by 44 to 55% across a meta-analysis of 13 RCTs, suppress NF-kB signaling, and inhibit the NLRP3 inflammasome. For autoimmune patients, this dual effect (weight loss plus direct inflammation reduction) makes GLP-1 agonists uniquely relevant.
Appetite suppression. AOD 9604 does not suppress appetite. Semaglutide's primary weight loss mechanism is appetite reduction through central nervous system GLP-1 receptor activation. For patients whose weight gain is driven by increased appetite (corticosteroid-induced, stress-related), this is a meaningful difference.
FDA status. AOD 9604: GRAS as food ingredient. Not approved as drug. Semaglutide: FDA-approved for type 2 diabetes (Ozempic) and obesity (Wegovy).
Cost. AOD 9604: $150 to $300 per month from compounding pharmacies. Semaglutide: $800 to $1,300 per month (branded), though compounded versions are available at lower cost. AOD 9604's lower cost is its primary practical advantage, though paying less for a treatment with minimal evidence is not obviously better value.
Safety data. AOD 9604: one 12-week trial, well-tolerated. Semaglutide: years of post-marketing surveillance, known side effect profile (nausea, gastroparesis risk, pancreatitis signal, potential thyroid concerns). Semaglutide has more documented side effects because it has been studied orders of magnitude more thoroughly.
The comparison is not close. Semaglutide has dramatically stronger evidence for weight loss and offers anti-inflammatory benefits that AOD 9604 does not. The only domain where AOD 9604 has an advantage is cost. For autoimmune patients making evidence-based decisions, this comparison should be clarifying.
Natural Alternatives with Stronger Evidence
Before considering any peptide for weight management, autoimmune patients should address foundational interventions that have better evidence.
Dietary modification (Grade A for weight loss, Grade B for autoimmune disease activity). The autoimmune diet reduces inflammatory triggers while supporting weight loss. Mediterranean diet patterns are associated with reduced RA disease activity and improved body composition. The AIP diet combines elimination of inflammatory foods with nutrient density.
Exercise to tolerance (Grade A). Even modest physical activity improves body composition and reduces inflammatory markers. For autoimmune patients limited by joint pain or fatigue, low-impact options (swimming, walking, yoga) still produce measurable benefit.
Sleep optimization (Grade B). Sleep restriction increases ghrelin, decreases leptin, and promotes weight gain. Many autoimmune patients have disrupted sleep from pain, anxiety, or medication effects. Addressing sleep quality supports weight management and reduces inflammatory markers.
Fasting mimicking diet (Grade B for autoimmune, Grade B for metabolic improvement). Five-day FMD cycles produce measurable reductions in body fat, CRP, and fasting glucose. A 2026 Nature Medicine trial showed immune regeneration effects in Crohn's disease. FMD addresses both weight and immune function simultaneously.
Dosing and Administration
The commonly reported protocol is 300 mcg per day via subcutaneous injection, administered in the morning in a fasted state. Cycles of 8 to 12 weeks are typical. Some protocols include cycling off for 4 weeks between treatment periods.
No evidence-based dosing protocol exists. The numbers above come from practitioner reports and compounding pharmacy recommendations, not from clinical trials establishing optimal dosing. The Phase 2 trial used oral administration at different doses; current subcutaneous protocols are extrapolated, not proven.
AOD 9604 is available from compounding pharmacies. Quality varies between suppliers. Verify third-party testing certificates. Do not purchase from unregulated online sources.
Any use should be discussed with a physician. Self-administration of injectable peptides without medical supervision is not recommended.
Side Effects and Safety
The Heffernan Phase 2 trial reported that AOD 9604 was well tolerated with no significant adverse events compared to placebo. The trial lasted 12 weeks and enrolled approximately 300 subjects.
No long-term safety data exists. No data on use beyond 12 weeks. No drug interaction studies have been published. No reproductive safety data. No carcinogenicity data.
The claim that AOD 9604 does not raise IGF-1 or cause insulin resistance is based on limited measurements from the Phase 2 trial and preclinical studies. These findings are reassuring but insufficient to establish a safety profile. A single 12-week trial cannot detect rare adverse events or long-term effects.
For autoimmune patients on immunosuppressants, biologics, or corticosteroids, there are no interaction data to guide decisions. The absence of known interactions is not the same as confirmed safety.
Should Autoimmune Patients Use AOD 9604?
The honest answer requires separating the legitimate need from the proposed solution.
The need is real. Weight management improves outcomes in RA, psoriatic arthritis, lupus, and other autoimmune conditions. Many patients face barriers to conventional weight management. The demand for effective, accessible tools is legitimate.
The solution is weak. AOD 9604 has Grade C evidence. The developer abandoned it. The clinical effect was modest. It has no anti-inflammatory properties. It costs $150 to $300 per month for a compound that has not been proven to work beyond one underwhelming trial.
Better options exist. GLP-1 agonists have Grade A evidence and anti-inflammatory effects. Dietary strategies have Grade A to B evidence and are available to everyone. Exercise, sleep, and stress management are foundational. The fasting mimicking diet offers metabolic and immune benefits simultaneously.
Our recommendation: prioritize evidence-based approaches first. If pharmacological weight management is needed, discuss GLP-1 agonists with your physician. AOD 9604 falls into the category of compounds with interesting biological rationale but insufficient clinical evidence to justify its cost or the act of injecting it daily.
For a broader view of peptides for autoimmune disease with evidence grades, see our hub article.
Frequently Asked Questions
Does AOD 9604 work for weight loss?
One Phase 2 trial (Heffernan et al. 2001) showed approximately 2 to 3 kg of additional fat loss over placebo across 12 weeks. The primary endpoint did not achieve statistical significance across all dose groups, and the developing company abandoned further clinical development. We grade AOD 9604 at Grade C (preliminary evidence only). For comparison, semaglutide produces 14.9% body weight loss in large RCTs with FDA approval.
Is AOD 9604 FDA-approved?
No. AOD 9604 has GRAS (Generally Recognized As Safe) status as a food ingredient (GRN 000678, 2014). GRAS status allows a substance to be added to food. It does not mean the FDA has approved AOD 9604 as a treatment for weight loss or any medical condition. The peptide industry frequently conflates GRAS status with drug approval. They are different regulatory categories.
Is AOD 9604 better than semaglutide?
No, by any evidence-based measure. Semaglutide has multiple large RCTs, FDA approval for obesity, 15 to 17% body weight reduction, and demonstrated anti-inflammatory effects (CRP reduction of 44 to 55%). AOD 9604 has one modest Phase 2 trial, no FDA drug approval, approximately 2 to 3 kg fat reduction, and no anti-inflammatory data. AOD 9604's only advantage is lower cost ($150 to $300/month vs $800 to $1,300/month for branded semaglutide).
Does AOD 9604 have side effects?
AOD 9604 was well tolerated in the single 12-week Phase 2 trial, with no significant adverse events versus placebo. It does not appear to raise IGF-1 levels or cause insulin resistance based on limited measurements. However, no long-term safety data exists, no drug interaction studies have been published, and no data extends beyond 12 weeks. The absence of detected problems in a small, short trial is not the same as an established safety profile.
Can AOD 9604 help with autoimmune-related weight gain?
Weight management genuinely improves outcomes in RA, psoriatic arthritis, and lupus by reducing adipose-derived inflammatory cytokines (TNF-alpha, IL-6, leptin). However, AOD 9604's Grade C evidence makes it a lower-priority tool compared to dietary modification, exercise, GLP-1 agonists (which also reduce inflammation directly), and fasting protocols. The need for weight management is valid. The evidence for this specific compound is not.
What is hGH fragment 177-191?
It is the technical designation for the region of human growth hormone that AOD 9604 derives from. Amino acids 176 through 191 constitute the C-terminal end of the growth hormone molecule, which contains the lipolytic (fat-burning) domain. AOD 9604 modifies this fragment by adding a tyrosine residue at position 177 to improve stability and enhance lipolytic activity while preventing IGF-1 stimulation.
Where the Evidence Stands
AOD 9604 occupies a familiar position in the peptide landscape: promising biological mechanism, insufficient clinical evidence, and marketing that far outpaces the science. The lipolytic mechanism is plausible. The single clinical trial suggests some biological activity. The company that knew the data best decided it was not worth pursuing.
For autoimmune patients, weight management is important enough to warrant evidence-based tools, not Grade C compounds with abandoned development programs. GLP-1 agonists, dietary strategies, exercise, and fasting protocols all offer stronger evidence and, in the case of GLP-1 agonists and fasting, direct anti-inflammatory benefits that AOD 9604 cannot provide.
If you are managing an autoimmune condition and struggling with weight, start with the interventions that have evidence behind them. A personalized protocol based on your specific condition, medications, and severity will serve you better than a peptide with one underwhelming trial.
Take the free 3-minute AutoimmuneFinder quiz to build a personalized, evidence-graded protocol matched to your specific condition, severity, and current medications.
This article is for educational purposes only and does not constitute medical advice. AOD 9604 is not FDA-approved for weight loss or any medical condition. GRAS status as a food ingredient does not constitute drug approval. Do not start any peptide therapy without consulting your physician. All treatment decisions should be made in partnership with your healthcare provider.